FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： HSBC Holdings plc 滙豐控股有限公司 呈交日期： 2025年8月15日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 00005 | 說明 | 普通股(每股0.50美元) | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 ...

Core Viewpoint - HSBC's stock price is currently around 100.6 HKD, showing increased short-term volatility with a 4.7% fluctuation over the past five days, indicating a tug-of-war between bulls and bears at a critical level [1][2]. Technical Analysis and Key Levels - Support levels for HSBC are identified at 96.5 HKD (short-term support) and 92.3 HKD (strong support), while resistance levels are at 104.4 HKD (recent high) and 108.5 HKD (yearly target) [2]. - The 10-day moving average (98.41 HKD) and 30-day moving average (98.16 HKD) have formed a "golden cross," but the stock price is nearing the upper Bollinger Band, making the ability to break through the psychological barrier of 100 HKD a focal point [2]. - There is speculation on whether HSBC will first retrace to the 96.5 HKD support if the broader Hong Kong market weakens, or if it will benefit from interest rate hike expectations to test higher levels [2]. Recent Performance and Investor Sentiment - In August, HSBC's stock price rose nearly 10% after a significant drop at the end of July, stabilizing around the 100 HKD mark [4]. - Investors are divided, with some seeing a double-top formation that could lead to a drop towards 90 HKD, while others believe the stock is on a stable upward trajectory [4]. Product Review and Strategy Insights - Recent product performance shows that UBS bull certificates have significantly outperformed the underlying stock, with one product rising 7% and another 10% despite only a 0.2% increase in the stock price [5]. - In the current market environment, investors are encouraged to consider UBS call options with a leverage of 17.3 times, particularly suitable for aggressive investors anticipating a breakout [7]. - For bearish investors, options with lower leverage and favorable implied volatility are also available, providing a range of choices depending on market outlook [7][11]. Market Volatility and Trading Opportunities - The current market volatility has increased the risk associated with bull and bear certificates, necessitating close monitoring of the distance between the stock price and the recovery price [11].

每经AI快讯，数据显示，8月14日，共10只港股获公司回购，2只个股回购金额超千万港元。其中，恒 生银行、美高梅中国、富智康集团回购金额最大，分别获公司回购2286.7万港元、1618.07万港元、 311.04万港元。截至8月14日，今年已有218只港股获公司回购，43只个股年内累计回购金额超亿港元。 其中，腾讯控股、汇丰控股、友邦保险年内累计回购金额最大，分别获公司回购400.43亿港元、222.01 亿港元、176.93亿港元。 ...

Market Overview - Most large-cap stocks experienced declines, with HSBC Holdings closing at HKD 103.043, up 2.63% from the previous close, while Tencent Holdings closed at HKD 585.875, down 0.70% [1][2] Stock Performance Summary - Tencent Holdings (00700) latest price: HKD 590.000, change: +HKD 4.000 (+0.68%), ADR price: HKD 585.875, decline: -HKD 4.125 (-0.70%) [2] - Alibaba Group (09988) latest price: HKD 121.800, change: -HKD 1.900 (-1.54%), ADR price: HKD 119.737, decline: -HKD 2.063 (-1.69%) [2] - HSBC Holdings (00005) latest price: HKD 100.400, change: -HKD 0.315 (-0.31%), ADR price: HKD 103.043, increase: +HKD 2.643 (+2.63%) [2] - AIA Group (01299) latest price: HKD 76.900, change: +HKD 0.500 (+0.65%), ADR price: HKD 76.338, decline: -HKD 0.562 (-0.73%) [2] - Meituan (03690) latest price: HKD 124.400, change: +HKD 0.100 (+0.08%), ADR price: HKD 121.813, decline: -HKD 2.587 (-2.08%) [2] - NetEase (099999) latest price: HKD 207.800, change: -HKD 7.600 (-3.53%), ADR price: HKD 203.157, decline: -HKD 4.643 (-2.23%) [2] - Hong Kong Exchanges and Clearing (00388) latest price: HKD 439.200, change: -HKD 0.600 (-0.14%), ADR price: HKD 435.548, decline: -HKD 3.652 (-0.83%) [2] - Ping An Insurance (02318) latest price: HKD 57.900, change: +HKD 1.100 (+1.94%), ADR price: HKD 57.146, decline: -HKD 0.754 (-1.30%) [2] - JD.com (09618) latest price: HKD 125.100, change: -HKD 2.300 (-1.81%), ADR price: HKD 123.693, decline: -HKD 1.407 (-1.13%) [2] - Kuaishou Technology (01024) latest price: HKD 75.200, change: +HKD 0.250 (+0.33%), ADR price: HKD 74.811, decline: -HKD 0.389 (-0.52%) [2]

Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]

Group 1 - The core index, the CESP50, experienced a decline of 0.28%, closing at 3170.29 points with a trading volume of 932.59 billion [1] - Over the past month, the CESP50 index has increased by 5.33%, by 8.84% over the last three months, and has risen by 26.77% year-to-date [1] - The CESP50 index is designed to reflect the overall performance of the top 50 blue-chip securities listed on the Hong Kong Stock Exchange under the "Hong Kong Stock Connect" program [1] Group 2 - The top ten holdings of the CESP50 index include Tencent Holdings (10.86%), HSBC Holdings (10.2%), Alibaba-W (9.9%), Xiaomi Group-W (6.25%), and others [1] - The index's holdings are entirely composed of securities from the Hong Kong Stock Exchange, with financials making up 39.60%, consumer discretionary 23.52%, and communication services 17.16% [2] - Other sectors represented in the index include information technology (8.46%), energy (3.94%), real estate (3.37%), utilities (1.66%), consumer staples (1.00%), industrials (0.83%), and healthcare (0.45%) [2]

大摩认为，中银香港(02388)股息回报将获支持，相信即将公布的中期业绩当中净息差将受压，但非利 息收入预料表现强劲，将关注管理层对信贷质素及资本管理的看法，予"减持"评级，目标价从24.7港元 上调至31.4港元。该行又指，恒生银行(00011)估值偏高，维持减持评级，目标价由93港元升至94.5港 元。 智通财经APP获悉，摩根士丹利发布研报称，上半年本地利率因素及信贷质素风险持续，一众银行股中 较偏好国际银行多于本地银行，因本地银行估值偏高，而国际性银行估值相对合理、资本回报具支持及 前景正面，维持对汇丰控股(00005)及渣打集团(02888)的"增持"评级。 （原标题：大摩：港银中偏好估值合理的国际性银行 予汇丰控股(00005)及渣打集团(02888)"增持"评 级） 该行认为，银行股第二季业绩将主要受HIBOR下跌及香港商业地产信贷质素恶化的影响，预料财富管 理业务及市场收入可抵销部分压力，但相信下半年挑战仍存在，预计银行净利息收入及净息差将于第三 季录得按季下跌，至第四季有望轻微复苏。随着美国利率预期下降，大摩预期2026年净息差可进一步收 窄。 ...

汇丰控股(00005)发布公告，该公司于2025年8月13日斥资1.65亿港元回购162.24万股股份，每股回购价 格为101.4-102.2港元。 于同日，斥资2210.83万英镑回购231.27万股股份，每股回购价格为9.525-9.605英镑;及注销240.92万股已 回购股份。 ...

格隆汇8月14日丨汇丰控股(00005.HK)发布公告，2025年8月13日耗资1.65亿港元回购162.24万股，回购 价格每股101.4-102.2港元。 ...

智通财经APP讯，汇丰控股(00005)发布公告，该公司于2025年8月13日斥资1.65亿港元回购162.24万股股 份，每股回购价格为101.4-102.2港元。 于同日，斥资2210.83万英镑回购231.27万股股份，每股回购价格为9.525-9.605英镑;及注销240.92万股已 回购股份。 ...